Skip to main content
NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.52%AUDCHF+0.43%GBPTRY+0.41%NZDCHF+0.41%USDCAD-0.39%EURCAD-0.34%CADJPY+0.34%GBPHKD+0.32%GBPUSD+0.30%GBPMXN-0.28%AUDSGD+0.28%USDTRY+0.28%EURCHF+0.27%NZDSGD+0.25%CHFJPY-0.25%GBPJPY+0.24%NZDUSD+0.23%AUDUSD+0.22%EURGBP-0.22%USDCHF+0.21%USDNOK-0.21%NZDCAD-0.20%GBPSGD+0.19%NZDMXN+0.18%USDZAR-0.18%AUDJPY+0.17%AUDCAD-0.17%EURSGD+0.16%USDILS+0.16%NZDJPY+0.16%NOKJPY+0.16%CHFSGD+0.15%USDPLN-0.15%USDSEK-0.15%EURAUD-0.14%CHFNOK-0.12%AUDDKK+0.12%EURNZD-0.12%SGDJPY-0.11%EURNOK-0.11%PLNJPY+0.10%EURHKD+0.10%USDDKK-0.10%GBPAUD+0.09%EURZAR-0.08%GBPCAD-0.08%EURCNH+0.07%GBPNZD+0.07%USDTHB+0.07%EURUSD+0.06%USDSGD+0.06%CHFSEK-0.06%GBPZAR-0.06%EURPLN-0.05%EURSEK-0.05%USDJPY-0.05%USDCOP-0.04%EURJPY+0.02%AUDNZD+0.02%USDCNH-0.02%USDMXN-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK+0.01%EURDKK0.00%COTTON+0.90%HG1+0.74%S1+0.42%XNGUSD+0.41%UKOIL-0.27%USOIL-0.26%W1-0.25%XAGUSD+0.09%GAGUSD+0.09%C1-0.05%GAUUSD+0.04%XAUUSD+0.04%BTCUSD+2.52%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.78%DOGEUSD+14.12%XMRUSDT+5.57%LINKUSD+13.42%XLMUSD+0.29%BCHUSDT+5.71%UNIUSD+7.23%LTCUSD+9.66%SUIUSD+3.56%HBARUSDT+0.50%TONUSD+26.15%TAOUSDT+3.92%AAVEUSD+3.69%DOTUSDT+0.06%ICPUSDT+0.56%ONDOUSDT+0.47%WLDUSDT+0.17%ARBUSDT+7.07%JUPUSDT+0.62%ATOMUSDT+1.62%INJUSDT+14.60%STXUSDT+5.78%FETUSDT+3.07%TIAUSDT+9.38%PYTHUSDT-0.53%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+21.23%GRTUSDT+3.94%IOTAUSDT+0.81%WIFUSDT+2.70%AXSUSDT-1.66%POLUSDT+2.83%FARTCOINUSDT+1.01%EOSUSDT+2.16%DYDXUSDT+3.68%GALAUSDT-1.87%ORDIUSDT+0.11%RONINUSDT-3.42%NOTUSDT+1.21%NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.52%AUDCHF+0.43%GBPTRY+0.41%NZDCHF+0.41%USDCAD-0.39%EURCAD-0.34%CADJPY+0.34%GBPHKD+0.32%GBPUSD+0.30%GBPMXN-0.28%AUDSGD+0.28%USDTRY+0.28%EURCHF+0.27%NZDSGD+0.25%CHFJPY-0.25%GBPJPY+0.24%NZDUSD+0.23%AUDUSD+0.22%EURGBP-0.22%USDCHF+0.21%USDNOK-0.21%NZDCAD-0.20%GBPSGD+0.19%NZDMXN+0.18%USDZAR-0.18%AUDJPY+0.17%AUDCAD-0.17%EURSGD+0.16%USDILS+0.16%NZDJPY+0.16%NOKJPY+0.16%CHFSGD+0.15%USDPLN-0.15%USDSEK-0.15%EURAUD-0.14%CHFNOK-0.12%AUDDKK+0.12%EURNZD-0.12%SGDJPY-0.11%EURNOK-0.11%PLNJPY+0.10%EURHKD+0.10%USDDKK-0.10%GBPAUD+0.09%EURZAR-0.08%GBPCAD-0.08%EURCNH+0.07%GBPNZD+0.07%USDTHB+0.07%EURUSD+0.06%USDSGD+0.06%CHFSEK-0.06%GBPZAR-0.06%EURPLN-0.05%EURSEK-0.05%USDJPY-0.05%USDCOP-0.04%EURJPY+0.02%AUDNZD+0.02%USDCNH-0.02%USDMXN-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK+0.01%EURDKK0.00%COTTON+0.90%HG1+0.74%S1+0.42%XNGUSD+0.41%UKOIL-0.27%USOIL-0.26%W1-0.25%XAGUSD+0.09%GAGUSD+0.09%C1-0.05%GAUUSD+0.04%XAUUSD+0.04%BTCUSD+2.52%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.78%DOGEUSD+14.12%XMRUSDT+5.57%LINKUSD+13.42%XLMUSD+0.29%BCHUSDT+5.71%UNIUSD+7.23%LTCUSD+9.66%SUIUSD+3.56%HBARUSDT+0.50%TONUSD+26.15%TAOUSDT+3.92%AAVEUSD+3.69%DOTUSDT+0.06%ICPUSDT+0.56%ONDOUSDT+0.47%WLDUSDT+0.17%ARBUSDT+7.07%JUPUSDT+0.62%ATOMUSDT+1.62%INJUSDT+14.60%STXUSDT+5.78%FETUSDT+3.07%TIAUSDT+9.38%PYTHUSDT-0.53%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+21.23%GRTUSDT+3.94%IOTAUSDT+0.81%WIFUSDT+2.70%AXSUSDT-1.66%POLUSDT+2.83%FARTCOINUSDT+1.01%EOSUSDT+2.16%DYDXUSDT+3.68%GALAUSDT-1.87%ORDIUSDT+0.11%RONINUSDT-3.42%NOTUSDT+1.21%
ZY

Zymeworks Inc. (ZYME)

NASDAQ • Healthcare

$25.07
-$0.25 (-1.0%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$25.04
Day Range$24.92 - $25.6
Avg. Volume (3M)1.1M
Market Cap$1.8B
52 Week Range
$16$31.34
Next EarningsIn 22 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$4.5M100%
Gross Profitminus cost of goods$4.5M100%

Fundamentals & Financials

Revenue (TTM)
$37.1M
Net Income (TTM)
-$149.9M
EPS (TTM)
-$2.02
ROA (TTM)
-37.78%
Current Ratio
6.32

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-57.1%Q1 2026-$0.55
-490.0%Q2 2026-$0.59
-7.9%Q3 2026-$0.62
Next

Nov 5

in 22 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -7.9%

Zymeworks’ revenue fell 90.6% year over year to about $4.6 million in the second fiscal quarter of 2026, reported August 6, 2026, while results were mixed versus consensus as revenue topped expectations but EPS trailed. Revenue of $4.6 million topped the $4.5 million estimate, +1.2%, and was down from $48.7 million a year ago, with gross profit also roughly $4.6 million. EPS came in at -$0.62, trailed the -$0.57 estimate by -$0.05, and compared with $0.03 a year ago, as the company posted an operating loss of about $42.2 million and a net loss of roughly $45.0 million versus net income of $2.3 million a year ago. Consensus for the next period calls for EPS of $2.42 on revenue of $231.9 million.

Next report — what to expect

Zymeworks Inc. (ZYME) reports earnings on November 5, 2026. Wall Street is looking for consensus EPS of $2.38 on consensus revenue of $229.6 million. For trailing context, revenue fell -90.6% year over year last quarter. Zymeworks has beaten EPS in 4 of 8 most recent quarters.

View full earnings history

About Zymeworks Inc.

Zymeworks Inc. is a NASDAQ-listed biotechnology company in the healthcare sector that develops biological therapies for cancer and remains in the clinical development stage. Its work centers on antibody-based drug candidates, and it generated $106.0 million of revenue in FY2025.

Name
Zymeworks Inc.
CEO
Kenneth H. Galbraith
Website
www.zymeworks.com
Industry
Healthcare
Year Founded
2003
Employees
231

Today's Snapshot

AI-generated

ZYME closed 1% below yesterday's close, in line with a weaker sector. Shares changed hands at about half as much again as its usual level.

Trading Volume

Above 10d avg 1.4M

2M

vs S&P 500 Today

Underperforming Market

-1.01%

Updated: October 13, 2026 at 20:27 UTC

Technical Indicators

2 Buy1 Neutral5 Sell
ZYME is biased to the downside as short- and mid-term moving averages sit above the current price while the stock is essentially at its 200-day level, creating a precarious position. Momentum measures are generally negative—CCI is deeply negative and MACD is below zero—while RSI is neutral and the ADX near 13 reflects a weak trend. Volatility is moderate with ATR around 4.8%, and OBV points to selling pressure; the classic pivot lies above the market. Technical takeaway: Sell — short/medium momentum is negative with price unable to clear key moving averages.
All signals
  • EMA (5 indicators)$25.00 - $26.26
    Sell
  • RSI (14)42.62
    Neutral
  • Stochastic %K (14, 3, 3)12.95
    Buy
  • MACD Level (12, 26)-0.42
    Sell

Peers & Related Assets

NRIXNurix Therapeutics, Inc.
$22.13-0.1%
CLDXCelldex Therapeutics, Inc.
$28.25-4.0%
XNCRXencor, Inc.
$23.52-6.1%
IMNMImmunome, Inc.
$17.58-8.2%
ADCTADC Therapeutics S.A.
$1.7-8.6%
CTMXCytomX Therapeutics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.